Published on

Rhode Island Sues Teva and Allergan for Fueling State Opioid Epidemic

The Rhode Island Attorney General Peter Neronha has settled over $100 million with Teva and Allergan pharmaceutical companies.

On Monday, Neronha filed a lawsuit against two big drug manufacturers for their contribution to the opioid epidemic in Rhode Island. The settlement includes $28.5 million in cash between Teva and Allergan, plus 1 million of Naloxone sprays and 67,000 Suboxone units. Both Naloxone and Suboxone help patients prevent possible opioid addiction.

Neronha claimed, “While no amount of money will ever be enough to undo the harm suffered by Rhode Islanders throughout the ongoing opioid epidemic, these additional recoveries will further support public health efforts to respond to the challenges brought on by this epidemic.”

The spokespersons of Teva Pharmaceutical Industries called the settlement “a critical step forward in getting life-saving treatments to the people who need them.”

Also read:US House Voted to End Trade Relations with Russia and Belarus

In a 424-8 vote, the US House of Representatives passed a bill to suspend normal trade relations with Russia and Belarus. If the Se...

Previously, in February 2021, the Rhode Island Attorney General sued McKinsey & Co. for $2.59 million for its assistance in broad anti-opioid drug promotion and gaining profit from the opioid crisis.

Special Offer
50+ essential legal templates for Your business and personal life
Special Offer
Article by Yevheniia Savchenko

Yevheniia Savchenko is a Legal Writer at Lawrina. Yevheniia browses through the most interesting and relevant news in the legal and legaltech world and collects them on Lawrina’s blog. Also, Yevheniia composes various how-to guides on legaltech, plus writes product articles and release notes for Loio, AI-powered contract review and drafting software.

Thank You! Welcome on board
We use Cookies to make Your experience on the Portal greater. To learn more about Cookies we use, please read Our Cookie Policy. Do you allow us to use Cookie?
Learn more Accept Cookies